

which comprises as an active ingredient the antigen-presenting cell of claim 22.

A5
25. (Amended) A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and the tumor antigen peptide or derivative thereof according to claim 9.

26. (Amended) A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and a tumor antigen peptide or derivative thereof, which complex is presented on the antigen-presenting cell of claim 22.

Sub C4
Add C5
28. (Amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or derivative thereof according to claim 9, the protein of claim 6, or the recombinant polypeptide of claim 19.

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The amendment to the claims is merely to delete improper multiple dependencies and thereby place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

If necessary, the Commissioner is hereby authorized in this,


Docket No. 0020-4872P

concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


John W. Bailey, #32,881

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

JWB/rem
0020-4872P

(Rev. 02/12/01)

0020-4872P

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

6 (Amended) A tumor antigen protein that is encoded by the DNA of [or 2, or is produced by the process of claim 5].

17. (Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides and derivatives thereof according to [any one of claims 9 to 16] claim 9.

18. (Amended) A recombinant DNA comprising at least one of DNAs that encode the tumor antigen peptides or derivatives thereof according to [any one of claims 9 to 16] claim 9.

21. (Amended) An antibody that specifically binds to [any one of] the protein of claim 6, [and the tumor antigen peptide or the derivative thereof according to any one of claims 9 to 16].

22. (Amended) An antigen-presenting cell wherein a complex between an HLA antigen and the tumor antigen peptide or the

derivative thereof according to [any one of claims 9 to 16] claim 9, is presented on the surface of a cell having antigen-presenting ability, which cell is isolated from a tumor patient.

24. (Amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient the antigen-presenting cell of claim 22 [or 23].

25. (Amended) A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and the tumor antigen peptide or derivative thereof according to [any one of claims 9 to 16] claim 9.

26. (Amended) A cytotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and a tumor antigen peptide or derivative thereof, which complex is presented on the antigen-presenting cell of claim 22 [or 23].

28. (Amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or derivative thereof according to [any one of claims 9 to 16] claim 9, the protein of claim 6, or the recombinant polypeptide of claim 19.